Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

BACKGROUND: Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted. To this end, the current study evaluates new targeted...

詳細記述

保存先:
書誌詳細
主要な著者: Giovannetti, E, Zucali, P A, Assaraf, Y G, Leon, L G, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A, Peters, G J
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2011
主題:
Translational Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3242521/
https://ncbi.nlm.nih.gov/pubmed/21970874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.400
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料